QIAGEN Beats Q2 2026 Estimates on Sample Tech Growth; Maintains Full-Year Outlook
Event summary
- Q2 2026 net sales held steady at $535M (CER), exceeding outlook for a ~2% decline.
- Sample technologies drove 5% CER growth, with consumables up high single digits and instruments mid-single digits.
- Adjusted diluted EPS of $0.62 beat guidance of at least $0.60.
- Full-year 2026 outlook reaffirmed: net sales growth of ~1-2% CER and adjusted diluted EPS of at least $2.43.
The big picture
QIAGEN's Q2 resilience highlights the stability of its Sample technologies pillar despite U.S. instrument spending challenges. The company's ability to maintain profitability while absorbing currency headwinds and investing in acquisitions reflects disciplined cost management. This performance comes amid broader industry trends toward automation and AI-driven diagnostics, where QIAGEN competes with larger players like Thermo Fisher Scientific and Roche Diagnostics.
What we're watching
- Product Momentum
- Whether new sample preparation systems and QIAcuity gene expression kits can sustain H2 growth acceleration.
- U.S. Market Pressures
- How continued instrument spending pressure in the U.S. will impact full-year performance.
- Parse Integration
- The pace at which Parse acquisition benefits materialize amid targeted investments.
Related topics